News tagged ‘BasicResearch’ clear
- Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science are collaborating with Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc., to identify which lung cancer patients would benefit from a new generation of immunotherapies and which combination of such therapies will be the most effective.
Tags: BasicResearch, LungCancer, Immunotherapy
- Dana-Farber and Brigham and Women's Hospital have launched Profile, one of the most comprehensive cancer research studies to help accelerate the development of personalized treatments for every person with cancer.
Tags: BasicResearch, Genomics, TargetedTherapy, Genetics
- In an effort to improve the success rate of investigational
cancer drugs entering clinical trials, the Center for Applied Cancer
Science (CACS) of the Dana-Farber Cancer Institute and Merck and Co.,
Inc., have established a collaboration to identify promising drug
targets, and develop therapeutic candidates to reach those targets.
- Genetic specialists at Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) are recommending that children being treated for sarcoma should be offered genetic counseling for Li-Fraumeni syndrome, a rare condition that greatly raises a person’s risk of developing additional cancers
Tags: BasicResearch, Genomics, Sarcoma
- Study finds delay of more than six weeks between surgery and radiation
makes local recurrence more likely, and could have implications for
younger women's risk of recurrence.
- Dana-Farber Cancer Institute and Children's Hospital Boston researchers have identified a protein that could be a powerful treatment target for sickle cell anemia, a significant global health problem, one that affects between 75,000 and 100,000 people in the United States alone.
- Research led by Dana-Farber/Boston Children's Cancer and Blood Disorders Center reports the discovery of a new genetic target for potential therapy of sickle cell disease.
Tags: BasicResearch, Genetics
- Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.
Tags: BasicResearch, BreastCancer, Genomics, OvarianCancer, GynecologicCancers
- Dr. Gimelbrant is mapping gene activation to better understand the
mechanisms essential for gene silencing. His findings could lead to the
design of highly customized cancer treatments.
Tags: BasicResearch, Genomics
- Scientists at Dana-Farber demonstrate that it’s possible, early in a tumor’s growth, to identify cancer genes that endow the tumor with the ability to metastasize. This is an important step toward developing prognostic tests for identifying early-stage tumors that are likely to spread and can be treated accordingly.
Tags: BasicResearch, Melanoma
Showing 31-40 of 124 items